Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings Of The Fortnight Expects An Increase In Life Sciences IPOs In 2013

This article was originally published in The Pink Sheet Daily

Executive Summary

Plus news of recent financings by the Pfizer animal health spin-out Zoetis, Bone Therapeutics, Ariad Pharmaceuticals and Foresight Capital Management.

You may also be interested in...



Foresite Capital Raises $300M Fund Focused On Life Sciences

San Francisco-based VC also is an investor in a $200 million Series DD funding for type 2 diabetes-focused Intarcia Therapeutics. Foresite will use the same investment strategy for its second fund, seeking late-stage investments in proven technologies with strong management and promising market positions.

Investors Crow For Shares Of Zoetis As It Begins Trading On The NYSE

Zoetis makes its debut on the public stock exchange, garnering the highest priced IPO since Facebook began trading last year.

Bone Therapeutics Raises $10.4M To Speed Phase III Cell Therapy Trials

Belgium's Bone Therapeutics raises $10.4 million in a Series D financing to fund a Phase III study of its lead product, an osteoblast cell therapy for osteonecrosis of the hip and non-union bone fractures.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075364

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel